About 19 results found for searched term "MOR agonist-2" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41810 | D3R/MOR antagonist 2 | Dopamine Receptor |
| D3R/MOR antagonist 2 is a D3R/MOR antagonist (Ki: 361 nM and 85.2 nM respectively). | ||
| M41886 | MOR agonist-2 | Opioid Receptor |
| MOR agonist-2 is a antagonist of D3R and agonist of MOR (Ki: 7.26 nM and 564 nM, respectively). | ||
| M1816 | Zibotentan | Endothelin Receptor |
| ZD4054 | ||
| Zibotentan (ZD4054) is a more selective and specific endothelin-A receptor (ETAR) antagonist with an IC50 value of 21 nM. | ||
| M3106 | UNC1215 | Epigenetic Reader Domain |
| UNC1215 is a potent and selective MBT (malignant brain tumor) antagonist, which binds L3MBTL3 with IC50 of 40 nM and Kd of 120 nM, 50-fold selective versus other members of the human MBT family. | ||
| M3161 | Betulinic acid | NF-κB |
| Lupatic acid; Betulic acid | ||
| Betulinic acid is a natural pentacyclic triterpenoid compound, which is an inhibitor of eukaryotic cell topoisomerase I with IC50 value of 5 μM. It has anti-inflammatory, anti-malaria, anti-AIDS and anti-tumor activities. Betulinic acid(Betulinic acid) is also an agonist of 20S proteasome. EC50=5.5μmol/L, Betulinic acid can specifically enhance cT-L activity of 20S proteasome. | ||
| M4552 | Nobiletin | Autophagy |
| Nobiletin is a citrus flavonoid with anti-inflammatory, anti-cancer, cholesterol lowering, memory protection activities. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes. | ||
| M10955 | Nemorexant | OX Receptor |
| ACT-541468 | ||
| Nemorexant (ACT-541468) is an effective orexin receptor antagonist. It also has IC50s of 2 nM and 3 nM for the Ox1 receptor and Ox2 receptor, respectively. | ||
| M21317 | EST73502 | Opioid Receptor |
| EST73502 is a selective, orally active, μ-opioid receptor (μ-opioid receptor/MOR) agonist and σ1 receptor (σ1R) antagonist that crosses the blood-brain barrier with Ki values of 64 nM and 118 nM for MOR and σ1R effects, respectively. EST73502 can be used in pain relief studies. | ||
| M28208 | Naldemedine tosylate | Opioid Receptor |
| S-297995 tosylate | ||
| Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. | ||
| M28907 | Relamorelin acetate | Ghrelin Receptor/GHSR |
| RM-131 acetate; BIM-28131 acetate | ||
| Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research. | ||
| M29841 | Relamorelin TFA | Ghrelin Receptor/GHSR |
| RM-131 TFA; BIM-28131 TFA | ||
| Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research. | ||
| M30443 | Relamorelin | Ghrelin Receptor/GHSR |
| RM-131; BIM-28131 | ||
| Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research. | ||
| M30676 | Ulimorelin | Ghrelin Receptor/GHSR |
| TZP-101 | ||
| Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition. | ||
| M30898 | Naldemedine | Opioid Receptor |
| S-297995 | ||
| Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CLpro encoded by SARS-CoV2 genome. | ||
| M38943 | Caulophyllogenin | PPAR |
| Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation. | ||
| M52993 | Endomorphin 2 | Opioid Receptor |
| Endomorphin 2, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. | ||
| M53886 | Endomorphin 1 | Opioid Receptor |
| Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. | ||
| M53887 | Endomorphin 1 acetate | Opioid Receptor |
| Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. | ||
| M58386 | Moringin | TRP Channel |
| Moringin is a potent and selective TRPA1 ion channel natural agonist with an EC50 of 3.14 μM. Moringin does not activate or activates very weakly the vanilloids somatosensory channels TRPV1, TRPV2, TRPV3 and TRPV4, and the melastatin cooling receptor TRPM8. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
